Literature DB >> 2432979

Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine.

A Giachetti, E Giraldo, H Ladinsky, E Montagna.   

Abstract

The selectivity profiles of the muscarinic receptor antagonists dicyclomine and trihexyphenidyl have been examined in binding and functional studies and compared with those of pirenzepine and atropine. Dicyclomine, trihexyphenidyl and pirenzepine demonstrated the highest affinity for the M1 muscarinic receptor subtype as revealed in competition experiments against [3H]-pirenzepine labelling of cortical membranes. Their affinity values lay in a narrow range (3.7-14 nM) approaching that of atropine (1.6 nM). Competition experiments against [3H]-N-methylscopolamine in cardiac and glandular (salivary) membranes revealed differences between the drugs examined. Dicyclomine, trihexyphenidyl and pirenzepine displayed low affinity for the cardiac and intermediate affinity for the glandular receptors. Thus, the drugs appeared to discriminate between the M1 (cortical) and the peripheral muscarinic subtypes (cardiac and glandular). However, atropine displayed similar affinities for either subtype with IC50s varying only slightly (1.6-4.6 nM). The rank order of selectivity was: pirenzepine greater than dicyclomine greater than trihexyphenidyl greater than atropine. Mirroring the binding data, pirenzepine, dicyclomine and trihexyphenidyl showed a tenfold greater ability at inhibiting M1-receptor mediated ganglionic responses (McN A-343 pressor effect in pithed rats and nictitating membrane contraction in cats) than at inhibiting peripheral muscarinic responses in the heart and cardiovascular smooth muscle (vagal bradycardia in rats and cats and vagally-induced vasodilatation in cats). The muscarinic antagonists so far examined can be categorized into two groups. Trihexyphenidyl, dicyclomine and pirenzepine, included in one group, are characterized by a higher affinity for the neuronal (M1) muscarinic receptor, hence they antagonize functional responses mediated by the M1 subtype. Atropine, a member of the other group, shows essentially no selectivity. 6 Differentiation of M1 and peripheral muscarinic receptor subtypes appears to be a property not confined to tricyclics such as pirenzepine but shared by diverse chemical structures. Both trihexyphenidyl and dicyclomine appear to be useful pharmacological tools in the classification of muscarinic receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2432979      PMCID: PMC1917044          DOI: 10.1111/j.1476-5381.1986.tb11123.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

Review 1.  Neurohumoral, hormonal, and drug receptors for the lower esophageal sphincter.

Authors:  R K Goyal; S Rattan
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682

2.  Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization.

Authors:  R Hammer; A Giachetti
Journal:  Life Sci       Date:  1982-12-27       Impact factor: 5.037

3.  [3h]pirenzepine selectively identifies a high affinity population of muscarinic cholinergic receptors in the rat cerebral cortex.

Authors:  M Watson; W R Roeske; H I Yamamura
Journal:  Life Sci       Date:  1982-11-01       Impact factor: 5.037

4.  The binding of agonists to brain muscarinic receptors.

Authors:  N J Birdsall; A S Burgen; E C Hulme
Journal:  Mol Pharmacol       Date:  1978-09       Impact factor: 4.436

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  [Anti-ulcer agent pirenzepine (LS 519)--a tricyclic compound with particular physico-chemical properties (author's transl)].

Authors:  W Eberlein; G Schmidt; A Reuter; E Kutter
Journal:  Arzneimittelforschung       Date:  1977-02

8.  Light microscopic autoradiographic localization of [3H]pirenzepine and [3H](-)quinuclidinyl benzilate binding in human stellate ganglia.

Authors:  H I Yamamura; M Watson; J K Wamsley; P C Johnson; W R Roeske
Journal:  Life Sci       Date:  1984-08-13       Impact factor: 5.037

9.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

10.  Modification of the binding properties of muscarinic receptors by gallamine.

Authors:  J M Stockton; N J Birdsall; A S Burgen; E C Hulme
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

View more
  18 in total

1.  Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory.

Authors:  R V Fornari; K M Moreira; M G Oliveira
Journal:  Learn Mem       Date:  2000 Sep-Oct       Impact factor: 2.460

2.  Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Authors:  Zixiu Xiang; Analisa D Thompson; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-12-01       Impact factor: 4.030

3.  Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart.

Authors:  E W Larson; M A Pfenning; E Richelson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Classifying neuronal subclasses of the cerebellum through constellation pharmacology.

Authors:  Kigen J Curtice; Lee S Leavitt; Kevin Chase; Shrinivasan Raghuraman; Martin P Horvath; Baldomero M Olivera; Russell W Teichert
Journal:  J Neurophysiol       Date:  2015-11-18       Impact factor: 2.714

5.  Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome.

Authors:  Surabi Veeraragavan; Nghiem Bui; Jennie R Perkins; Lisa A Yuva-Paylor; Randall L Carpenter; Richard Paylor
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

6.  Subclassification of atrial and intestinal muscarinic receptors of the rat--direct binding studies with agonists and antagonists.

Authors:  F Brunner
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

7.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

8.  Loss of muscarinic antinociception by antisense inhibition of M(1) receptors.

Authors:  C Ghelardini; N Galeotti; A Bartolini
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

9.  Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: comparison with hippocampal M1, atrial M2 and ileal M3 receptors.

Authors:  M H Richards
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

10.  Evidence for facilitatory and inhibitory muscarinic receptors on postganglionic sympathetic nerves in mouse isolated atria.

Authors:  M Cost; H Majewski
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.